Humira Drug Market Report 2026

The humira drug market size has grown strongly in recent years. It will grow from $10.33 billion in 2025 to $11.08 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising arthritis prevalence, increasing awareness of biologics, patent exclusivity of humira, growth of specialty clinics, regulatory approvals for rheumatoid arthritis, increasing healthcare spending, limited biosimilar penetration, advancements in injection technology, increasing hospital adoption, high unmet medical needs.

The humira drug market size is expected to see strong growth in the next few years. It will grow to $15.23 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to expansion of biosimilars, increasing patient preference for self-administration, rising telemedicine adoption, growing geriatric population, expansion in emerging markets, innovation in pre-filled pen delivery, increasing government support for biologics, integration with digital health platforms, personalized medicine trends, improved insurance coverage. Major trends in the forecast period include personalized arthritis treatment, biologic therapy adoption, home-based injection solutions, combination therapy approaches, telemedicine integration.

The increasing incidence of autoimmune diseases is anticipated to drive the growth of the Humira drug market in the coming years. Autoimmune diseases occur when the body’s immune system mistakenly attacks and damages healthy tissues and cells. Humira is widely used to manage pain and inflammation associated with several autoimmune conditions, and a rise in the number of such disorders directly increases demand for this therapy. For example, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organization, it was estimated that by 2025 around 562,378 Australians would be living with rheumatoid arthritis, representing about 14% of the total arthritis population. Therefore, the rising incidence of autoimmune diseases is contributing to the growth of the Humira drug market.

Major companies operating in the Humira drug market are increasingly focusing on the development of biosimilars to improve affordability and accessibility. Manufacturers are emphasizing cost-effective alternatives by producing high-quality biosimilars that are comparable to Humira. For instance, in October 2023, Boehringer Ingelheim, a Germany-based pharmaceutical company, launched a biosimilar version of Humira. Boehringer Ingelheim’s product is among the few Humira biosimilars approved by the U.S. Food and Drug Administration as interchangeable, allowing it to be substituted for the reference product without requiring a new prescription.

In August 2023, CVS Health Corporation, a US-based pharmacy and healthcare company, partnered with Sandoz Group AG to develop a lower-cost alternative to Humira. This collaboration aims to produce a near-identical biosimilar at a significantly reduced price, helping CVS Health strengthen its position in the rapidly expanding biosimilars market. As part of the partnership, Cordavis, a new subsidiary associated with Novartis, was established to focus on securing the supply of novel biosimilar medicines, further supporting market competition and patient access.

Major companies operating in the humira drug market are AbbVie Inc., Amgen Inc., Sandoz International GmbH, Viatris Inc., Samsung Bioepis Co Ltd., Coherus BioSciences Inc., Celltrion Healthcare Co Ltd., Alvotech Holdings S.A, Biocad Biopharmaceutical Company, Fujifilm Kyowa Kirin Biologics Co Ltd, Alteogen Inc, Bio-Thera Solutions Ltd, Momenta Pharmaceuticals Inc, Innovent Biologics Inc, CinnaGen Co, Hetero Healthcare Ltd, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals Ltd, Cadila Pharmaceuticals Ltd, Mochida Pharmaceutical Co Ltd.

North America was the largest region in the humira drug market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the humira drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the humira drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical imports have created both challenges and opportunities for the Humira drug market by increasing costs for active pharmaceutical ingredients and imported delivery devices. The resulting price fluctuations impact segments such as Humira Syringe and Humira Pen, especially in regions like North America and Europe, which rely on global supply chains. Specialty clinics and hospitals face higher procurement costs, potentially slowing adoption, while domestic manufacturers may benefit from increased local production incentives. Overall, tariffs drive both cost pressures and localized innovation strategies within the market.

The humira drug market research report is one of a series of new reports that provides humira drug market statistics, including humira drug industry global market size, regional shares, competitors with a humira drug market share, detailed humira drug market segments, market trends and opportunities, and any further data you may need to thrive in the humira drug industry. This humira drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Humira, also known as adalimumab, is an injectable medication prescribed to treat rheumatoid arthritis and several other inflammatory conditions. It is used to reduce pain and swelling associated with various forms of arthritis and related disorders.

The main types of Humira drugs include Humira syringes and Humira pens. A Humira syringe is a form of treatment used to manage progressive rheumatoid arthritis. The drug is also used for applications such as ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease, and others, and is utilized by end users including hospitals, specialty clinics, and other healthcare settings.

The humira drug market consists of sales of single-dose pen, a single-dose prefilled syringe, and a single-dose vial of liquid solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.